Araris Biotech AG is a biotechnology start-up based in Zurich, Switzerland, that specializes in developing antibody-drug conjugate (ADC) linker technology for targeted chemotherapy. Founded in 2019, the company focuses on creating a platform that facilitates the rapid production of high-quality ADCs without the need for extensive engineering of antibodies or cell lines. This approach allows for the direct use of "off-the-shelf" antibodies, enabling the site-specific modification of ADCs within days, while ensuring robust quality control and analysis. Araris' technology is designed to deliver potent drugs directly to cancer cells, minimizing exposure to healthy tissues and thereby improving safety and tolerability for patients. The company's innovative ADC technology is supported by two patents, underscoring its commitment to advancing anti-cancer treatment options.
NovaGo Therapeutics AG researches and develops human antibody therapeutics targeting cerebral stroke and spinal cord injury. The company’s products stimulate nerve repair and regeneration. Its products are recombinant human monoclonal antibodies targeting the nerve outgrowth inhibitor Nogo-A. The company has a strategic partnership with Neurimmune Holding AG. NovaGo Therapeutics AG was founded in 2015 and is based in Schlieren, Switzerland.